Tritonpoint Wealth LLC Sells 3,322 Shares of Danaher Co. (NYSE:DHR)

Tritonpoint Wealth LLC decreased its position in shares of Danaher Co. (NYSE:DHR) by 4.1% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 77,073 shares of the conglomerate’s stock after selling 3,322 shares during the period. Danaher makes up about 1.5% of Tritonpoint Wealth LLC’s investment portfolio, making the stock its 12th largest position. Tritonpoint Wealth LLC’s holdings in Danaher were worth $15,825,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Spinnaker Trust grew its holdings in shares of Danaher by 1.2% in the fourth quarter. Spinnaker Trust now owns 4,304 shares of the conglomerate’s stock worth $988,000 after purchasing an additional 50 shares during the last quarter. Fortis Capital Advisors LLC grew its holdings in Danaher by 1.3% during the 4th quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate’s stock worth $914,000 after acquiring an additional 50 shares in the last quarter. Fayez Sarofim & Co grew its holdings in Danaher by 0.6% during the 4th quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate’s stock worth $1,902,000 after acquiring an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC grew its holdings in Danaher by 4.8% during the 4th quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate’s stock worth $252,000 after acquiring an additional 50 shares in the last quarter. Finally, Perennial Investment Advisors LLC grew its holdings in Danaher by 2.2% during the 4th quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate’s stock worth $538,000 after acquiring an additional 51 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president now owns 15,179 shares of the company’s stock, valued at $3,005,442. The trade was a 51.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the sale, the chairman now directly owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. This trade represents a 28.70% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is owned by insiders.

Danaher Price Performance

NYSE:DHR opened at $200.51 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The firm has a market cap of $143.50 billion, a price-to-earnings ratio of 37.98, a price-to-earnings-growth ratio of 2.66 and a beta of 0.77. The company has a 50 day moving average price of $192.80 and a 200-day moving average price of $211.19. Danaher Co. has a 1-year low of $171.00 and a 1-year high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping the consensus estimate of $1.62 by $0.26. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. Danaher had a net margin of 16.33% and a return on equity of 10.82%. Equities research analysts forecast that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.64%. Danaher’s payout ratio is presently 24.85%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on DHR shares. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. The Goldman Sachs Group lowered their price target on shares of Danaher from $260.00 to $240.00 and set a “neutral” rating on the stock in a report on Wednesday, April 23rd. Wells Fargo & Company lowered their price target on shares of Danaher from $240.00 to $210.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 23rd. Stifel Nicolaus upgraded shares of Danaher from a “hold” rating to a “buy” rating and set a $260.00 price target on the stock in a report on Friday, March 14th. Finally, UBS Group lowered their price target on shares of Danaher from $275.00 to $240.00 and set a “buy” rating on the stock in a report on Wednesday, April 23rd. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $248.17.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.